This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miranda, J M Articles by Jara, L J Search for Related Content PubMed PubMed Citation Articles by Miranda, J M Articles by Jara, L J Social Bookmarking                         What's this?

Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis

R E Prieto

Rheumatology Department, Centro Meádico Nacional La Raza

R Paniagua

G Garcia

D Amato

Unidad de Investigacioán en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social, Mexico City, Mexico

L Barile

L J Jara

Rheumatology Department, Centro Meádico Nacional La Raza

Prolactin (PRL) has been involved in the pathogenesis of systemic lupus erythematosus (SLE) and hyperprolactinemia has been connected with systemic activity. However, the clinical significance of PRL has not been investigated in lupus glomerulonephritis (GN). Methods: We studied SLE patients (ACR criteria) with biopsy-proven renal disease. Renal histology was classified according to World Health Organization (WHO) criteria. Renal function tests, albuminuria, complement levels (nephelometry), anti-DNA antibodies (C. luciliae) and serum and urine PRL concentrations (RIA) were determined at baseline and at 4-month intervals for one year. Renal activity was defined as mild, moderate or severe according to serum creatinine, creatinine clearance, albuminuria, red blood cells (RBC), and casts. Results: There were 26 patients with mean age 28.5 y and mean disease duration 47.9 months. Twenty patients had diffuse proliferative glomerulonephritis (GN), four had focal GN and two had membranous GN with proliferative changes. Renal activity was mild in ten patients, moderate in ten and severe in six. Mean serum (24.7 5.3) and urine (0.90 0.36) PRL levels were higher in patients with severe renal activity (P < 0.05 compared with mild group). PRL levels decreased after treatment, but this trend was not uniform during the follow-up period. Conclusion: Hyperprolactinemia was prevalent in SLE patients and high levels of PRL in the serum and urine could be related to severe renal disease.

Key Words: prolactin • glomerulonephritis • systemic lupus erythematosus

Lupus, Vol. 7, No. 6, 387-391 (1998)
DOI: 10.1191/096120398678920307


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Gerlo, P. Verdood, B. Gellersen, E. L. Hooghe-Peters, and R. Kooijman Mechanism of Prostaglandin (PG)E2-Induced Prolactin Expression in Human T Cells: Cooperation of Two PGE2 Receptor Subtypes, E-Prostanoid (EP) 3 and EP4, Via Calcium- and Cyclic Adenosine 5'-Monophosphate-Mediated Signaling Pathways J. Immunol., November 15, 2004; 173(10): 5952 - 5962. [Abstract] [Full Text] [PDF]

				C C Mok and C S Lau Pathogenesis of systemic lupus erythematosus J. Clin. Pathol., July 1, 2003; 56(7): 481 - 490. [Abstract] [Full Text] [PDF]

				S E Walker and L.-y. Yu-Lee Overview: prolactin and autoimmunity Lupus, October 1, 2001; 10(10): 659 - 659. [PDF]

				L J Jara, O Vera-Lastra, J M Miranda, M Alcala, and J Alvarez-Nemegyci Prolactin in human systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 748 - 756. [Abstract] [PDF]

				A M Jacobi, W Rohde, M Ventz, G Riemekasten, G-R Burmester, and F Hiepe Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity Lupus, August 1, 2001; 10(8): 554 - 561. [Abstract] [PDF]

				S E Walker Treatment of systemic lupus erythematosus with bromocriptine Lupus, March 1, 2001; 10(3): 197 - 202. [Abstract] [PDF]

				A M Jacobi, W Rohde, H-D Volk, T Dorner, G-R Burmester, and F Hiepe Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls Ann Rheum Dis, March 1, 2001; 60(3): 242 - 247. [Abstract] [Full Text] [PDF]

				S E Walker, D Miller, D L Hill, and G R Komatireddy Prolactin, a pituitary hormone that modifies immune responses: Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico Lupus, July 1, 1998; 7(6): 371 - 375. [PDF]